Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics.

The Journal of biological chemistry - 1 Oct 2023

Kim Minsoo, McDonald Eli Fritz, Sabusap Carleen Mae P, Timalsina Bibek, Joshi Disha, Hong Jeong S, Rab Andras, Sorscher Eric J, Plate Lars

Abstract excerpt

Cystic fibrosis (CF) is one of the most prevalent lethal genetic diseases with over 2000 identified mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Pharmacological chaperones such as lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445) treat mutation-induced defects by stabilizing CFTR and are called correctors. These correctors improve proper folding and thus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodioxoles
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Gene Knockdown Techniques

Share to Protein Biosynthesis

Share to Proteostasis

Share to Pyrazoles

Share to Ribosomal Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37690692
DOI: 10.1016/j.jbc.2023.105242
PMCID: PMC10579539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics.PMID 37690692Read ↗

Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamicsSemantic proximity Read ↗

Distinct proteostasis states drive pharmacologic chaperone susceptibility for Cystic Fibrosis Transmembrane Conductance Regulator misfolding mutantsSemantic proximity Read ↗

Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants.Semantic proximity Read ↗

Elucidation of Global Trends in the Effects of VX-661 and VX-445 on the Expression of Clinical CFTR VariantsSemantic proximity Read ↗

Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response VulnerabilitySemantic proximity Read ↗

Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding statesSemantic proximity Read ↗

Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states.Semantic proximity Read ↗

General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR VariantsSemantic proximity Read ↗

General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants.Semantic proximity Read ↗

Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.Semantic proximity Read ↗

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.Semantic proximity Read ↗

General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.